Dashboard
Weak Long Term Fundamental Strength with a 6.58% CAGR growth in Net Sales over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.99
Positive results in Sep 26
Stock is technically in a Mildly Bullish range
With ROE of 20.5, it has a Very Attractive valuation with a 2.9 Price to Book Value
Majority shareholders : Non Institution
Stock DNA
Pharmaceuticals & Biotechnology
INR 32 Cr (Micro Cap)
14.00
40
0.00%
-0.65
20.47%
2.94
Total Returns (Price + Dividend) 
Guj. Terce Labs. for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Gujarat Terce Laboratories Ltd is Rated Sell
Gujarat Terce Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 Oct 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 October 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.
Read More
Gujarat Terce Laboratories Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals
Gujarat Terce Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The pharmaceutical micro-cap’s recent price surge of 9.10% to ₹38.00 reflects renewed market interest, although underlying financials remain subdued. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced the rating change on 6 October 2026.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
07-Nov-2026 | Source : BSEDetailed disclosure is attached.
Unaudited Standalone Financial Results Of The Company For The Second Quarter And Half Year Ended 30 September 2026
05-Nov-2026 | Source : BSEDetailed disclosure is attached.
Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended From Time To Time (Listing Regulations)
05-Nov-2026 | Source : BSEDetailed disclosure is attached.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 0 FIIs
Aalap Natubhai Prajapati (17.35%)
Sagar Saxena (1.35%)
54.23%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 42.00% vs -21.05% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 833.33% vs -280.00% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is -5.60% vs 10.73% in Sep 2024
Growth in half year ended Sep 2025 is -2.86% vs 244.33% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is -4.75% vs 5.87% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -12.03% vs 903.33% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is -5.44% vs 4.65% in Mar 2025
YoY Growth in year ended Mar 2026 is 324.49% vs -508.33% in Mar 2025